All In Biotech

Drug Trial Radar · NCT05192200

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO ADULT PARTICIPANTS ≥18 AND ≤80 WITH ACTIVE DERMATOMYOSITIS.

Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Dec 20, 2021

Primary completion

Nov 20, 2023

Study completion Nov 20, 2023

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

Conditions

  • Dermatomyositis

Interventions

  • Anti-Beta Interferon (PF-06823859)Drug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 of dosing maximum up to Week 68
  2. Number of Participants With Laboratory AbnormalitiesTime frame: From Day 1 of dosing maximum up to Week 68
  3. Number of Participants According to Categorization of Changes in Vital SignsTime frame: From Day 1 of dosing maximum up to Week 68
  4. Number of Participants According to Categorization of Electrocardiogram (ECG) FindingsTime frame: From Day 1 of dosing maximum up to Week 68

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Alabama at Birmingham, Department of Dermatology

    Birmingham, Alabama

  • Mayo Clinic

    Scottsdale, Arizona

  • Attune Health Research Inc.

    Beverly Hills, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)

    Fairway, Kansas

  • KU Clinical and Translational Science Unit (CTSU) Rainbow

    Kansas City, Kansas

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Brigham & Women's Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital - CTH

    Boston, Massachusetts

  • Center for Outpatient Health

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • NYU Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology

    New York, New York

  • NYU Langone Health Clinical Research Center

    New York, New York

  • NYU Langone Radiology - Ambulatory Care Center East 41st Street

    New York, New York

  • Mount Sinai Doctors Dermatology

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Center for Human Phenomic Science

    Philadelphia, Pennsylvania

  • University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM)

    Philadelphia, Pennsylvania

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary

  • Centrum Medyczne Plejady

    Krakow, Poland

  • Nova Reuma Społka Partnerska

    Bialystok, Podlaskie Voivodeship, Poland

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.